Zacks Investment Research upgraded shares of AC Immune (NASDAQ:ACIU) from a sell rating to a hold rating in a research note released on Monday morning.
According to Zacks, “AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company’s pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland. “
Separately, BidaskClub upgraded shares of AC Immune from a buy rating to a strong-buy rating in a research report on Wednesday, December 27th.
Shares of AC Immune (NASDAQ ACIU) opened at $12.60 on Monday. AC Immune has a 12-month low of $6.03 and a 12-month high of $13.91.
AC Immune (NASDAQ:ACIU) last announced its quarterly earnings results on Monday, November 13th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. sell-side analysts expect that AC Immune will post -0.57 earnings per share for the current year.
Hedge funds have recently made changes to their positions in the stock. Wells Fargo & Company MN acquired a new position in shares of AC Immune in the third quarter valued at approximately $111,000. Goldman Sachs Group Inc. acquired a new position in shares of AC Immune in the second quarter valued at approximately $127,000. Janney Montgomery Scott LLC acquired a new position in shares of AC Immune in the third quarter valued at approximately $134,000. Finally, Belpointe Asset Management LLC acquired a new position in shares of AC Immune in the third quarter valued at approximately $571,000. Hedge funds and other institutional investors own 17.12% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “AC Immune (ACIU) Upgraded to Hold at Zacks Investment Research” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/06/ac-immune-aciu-upgraded-to-hold-at-zacks-investment-research.html.
About AC Immune
AC Immune SA is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms.
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.